STOCKHOLDERS' EQUITY

6 Months Ended

Aug. 31, 2022

Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 11 – STOCKHOLDERS’ EQUITY

Stock-based compensation expense is included in the following captions of the condensed consolidated statements of comprehensive loss (in thousands):

	Three Months Ended				Six Months Ended
	August 31,				August 31,
	2022		2021		2022		2021
Cost of revenues	$	30	$	795	$	85	$	789
Research and development		672		321		1,436		1,031
Selling and marketing		749		979		1,309		1,623
General and administrative		1,745		723		3,326		1,783
Other non-operating expense		-		119		-		183
	$	3,196	$	2,937	$	6,156	$	5,409

Changes in our outstanding stock options during the six months ended August 31, 2022 were as follows (options in thousands):

	Number of Options		Weighted Average Exercise Price		Weighted average remaining contractual life (years)		Aggregate intrinsic value
Outstanding at February 28, 2022		664	$	16.38		5.4
Granted		—		—
Exercised		—		—
Forfeited or expired		—		—
Outstanding at August 31, 2022		664	$	16.38		4.9	$	-
Exercisable at August 31, 2022		577	$	15.94		4.8	$	-

Changes in our outstanding restricted stock shares, performance stock units (“PSUs”) and restricted stock units (“RSUs”) during the six months ended August 31, 2022 were as follows (restricted shares, PSUs and RSUs in thousands):

	Number of Restricted Shares, PSUs and RSUs			Weighted Average Grant Date Fair Value		Shares Retained to Cover Statutory Withholding Taxes
Outstanding at February 28, 2022		2,940		$	10.39
Granted		2,237			4.65
Vested		(857	)		11.14		327
Forfeited		(198	)		11.13
Outstanding at August 31, 2022		4,122		$	7.09

As of August 31, 2022, there was $24.0 million of total unrecognized stock-based compensation cost related to outstanding nonvested equity awards that is expected to be recognized as an expense over a weighted-average remaining vesting period of 2.3 years.